DOCSLIB.ORG

Pharma Cutting-Edge Swiss Companies Groundbreaking Medicine | Big Data | the Fight Against Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharma Cutting-Edge Swiss Companies Groundbreaking Medicine | Big Data | the Fight Against Cancer N°4 SEPTEMBER 2017 WWW.SWISSQUOTE.COM CHF 9.- FINANCE AND TECHNOLOGY UNPACKED BOSSARD The Swiss family business that rolls with Tesla COMAC Chinese manufacturer up against Airbus and Boeing MCDONALD’S Under pressure, the fast-food giant reinvents itself DOSSIER PHARMA CUTTING-EDGE SWISS COMPANIES GROUNDBREAKING MEDICINE | BIG DATA | THE FIGHT AGAINST CANCER ROCHE NOVARTIS IDORSIA ACTELION BASILEA SANTHERA SIEGFRIED Boutiques OMEGA: Zürich Genève Luzern Interlaken Bern CransMontana Zermatt Bürgenstock The classic in a new light USM Modular Furniture Haller now features revolutionary integral lighting: cable-free, dimmable, energy efficient. A true innovation – get inspired! www.usm.com Visit our authorized sales partners or our USM Showrooms in Berlin, Bern, Düsseldorf, Hamburg, London, Munich, New York, Paris, Stuttgart, Tokyo usm_swissquote_hallerE_2017.indd 2 06.04.17 08:13 EDITORIAL SWISSQUOTE SEPTEMBER 2017 Banks, watches and...pharma By Marc Bürki, CEO of Swissquote anks, watches and dream, personalised medicine is p. 38 chocolate. For the rest of benefitting from constant progress the world, Switzerland’s in genetics and genomics and is Breputation consistently boils down little by little becoming a reality. to these three things, according to the “ Swissness Worldwide ” But don’t miss the next big thing : the study, an interview of thousands digitisation of data and big data is of people in several countries shaking up the world of big pharma. conducted at regular intervals Who knows ? Companies outside by the University of St. Gallen. the industry, such as Google or Apple, could come onto the scene However, one look at the half-year next. It wouldn’t be a surprise to press releases from the Swiss Thomas Cueni, Director General of p. 54 Federal Customs Administration the International Federation of Phar- shows a far more nuanced and maceutical Manufacturers & Asso- comprehensive picture of what is ciations (IFPMA), who we interview really going on in the country. What in this issue. That’s because the stands out is the pharmaceutical pharmaceutical industry, while on industry’s rise to power, year after the cutting-edge of R&D, is con- year, as the top driver of Swiss servative in its operations and still exports well ahead of other indus- relies on rather traditional models. tries. No less than 40% of Swiss A recent McKinsey study showed exports now come from this sector, that the sector is falling behind in a pillar of the national economy. The terms of “ digital maturity ” and is number of jobs on Swiss soil that far behind other industries such are directly or indirectly associated as tourism, media and banking. with pharma is close to 200,000. But for how long ? After heavyweights like Roche and In addition to the feature on pharma, Novartis, which regularly rank among this issue of Swissquote Magazine, the top five pharma companies which is decidedly very Swiss, also in the world in terms of turnover, takes a never-before-seen look p. 34 there are other promising Swiss at Zug-based Bossard. With 2,000 p. 20 companies, as well as a myriad of employees, this company is a market burgeoning start-ups across the jewel but still relatively unknown. country. A commonality among the It specialises in fastening tech- majority of these Swiss players is nologies (screws, nuts and bolts, their ability to innovate. Roche and etc.), particularly for high-tech Novartis are the top two companies industries such as aeronautics, and globally when it comes to investments is currently the official supplier in pharma R&D (Roche leads the for US auto manufacturer Tesla. way with nearly 8 billion invested in 2016). Long considered a futuristic Happy reading ! 4 SWISSQUOTE SEPTEMBer 2017 20 BOSSARD 26 28DOSSIER PHARMA CUTTING-EDGE SWISS COMPANIES COMAC TABLE OF CONTENTS 3. EDITORIAL 20. BOSSARD 28. DOSSIER : PHARMA by Marc Bürki The Swiss family CUTTING-EDGE SWISS COMPANIES business that 6. SCANS rolls with Tesla 33. Infographic : 44. In the shadows of the Economic Pharma in figures pharma industry, clinical survey 24. FOCUS trials prosper Saudi Arabia is 34. Five Swiss firms 16. TRENDS open for business in the forefront 50. When pharma out- Personalities, sources production st nations, 26. ANALYSIS 38. 21 century medicine 54. Interview with Thomas innovations Chinese aircraft 42. Infographic : Cueni, Director General manufacturer, How a drug is made of the International 18. THE MATCH COMAC, takes on Federation of Pharma- Easyjet vs Ryanair Airbus and Boeing ceutical Manufacturers & Associations (IFPMA) 5 TABLE OF CONTENTS SWISSQUOTE SEPTEMBER 2017 BURGERS 58 PUBLISHER Swissquote Chemin de la Crétaux 33 1196 Gland – Suisse +41 44 825 88 88 www.swissquote.com [email protected] Manager Brigitta Cooper EDITORIAL Editor-in-chief Ludovic Chappex 66 Design director Natalie Bindelli and Caroline Fischer CANA atelier graphique Route de Jussy 29 – 1226 Thônex www.ateliercana.ch Editorial staff Stanislas Cavalier, Sophie Gaitzsch, Benjamin Keller, Salomé Kiner, Oscar Lemaire, Marie Maurisse, Philipp Müller, Gaëlle Sinnassamy, GAMING Julie Zaugg Layout 72 Natalie Bindelli, Caroline Fischer, Coralie Meder (CANA atelier graphique) Cover NBC Universal Photography Nicolas Righetti, AFP, Keystone, iStockphoto, Newscom, Reuters MEXICO Editing (English version) Ose Ayewoh, Marco Simon Translation Technicis Finance PRINTING, BINDING AND DISTRIBUTION Stämpfli Ltd. 58. MCDONALD’S 72. TRAVEL Wölflistrasse 1 – 3001 Bern The revenge of the burger La dolce vita in Mexico www.staempfli.com ADVERTISING 62. SWISSQUOTE 76. CARS Infoplus AG The platform of choice Small SUVs Traubenweg 51, CH-8700 Küsnacht for investing in Bitcoin take the spotlight [email protected] WEMF 65. APPS AND BOOKS 80. PRIVATE ISSUES REMP 2017 : 50,638 ex. Print run : 60,000 ex. The selection of the month : Lea von Bidder, to read and download co-founder of Ava and L’inouï 66. GAMING The battle between four SUBSCRIPTIONABONNEMENT of the major publishers CHF 40.-40 FOR pour 6 6ISSUES numéros www.swissquote.ch/magazinewww.swissquote.ch/magazine/f/ BOSSARD /WANG JILIANG, AFP / ISTOCKPHOTO BLIZZARD ACTIVISION GLADYS GARA BOSSARD /WANG 6 SCANS SWISSQUOTE SEPTEMBER 2017 SCANS engineering OC OERLIKON TAKES ON 3D PRINTING OC Oerlikon – a Pfaeffikon-based company in the Canton of Schwyz – is set to invest 300 million Swiss francs in 3D printing materials over the next five years. Last July, in an interview for the e-paper Schweiz am Wochenende, group CEO Roland Fischer revealed his turnover target of 300 million Swiss francs by 2020, representing a market share of 15%. According to Fischer, the primary areas “ This is not served would be medical prosthetics, aeronautics and the automotive industry. OC Oerlikon plans a Tinder to manufacture advanced metal powders for 3D printing and will even print certain components relationship ” in-house for its customers. The Swiss company The CEO of Whole Foods, also announced a partnership in June with General John Mackey, commenting on Electric, one of the biggest 3D printing system the buyout of the organic manufacturers. OERL supermarket chain by Amazon energy RISE OF ELECTRIC CARS WORRIES OPEC The new Volvo XC60 SUV. The Swedish automotive company announced that +70% beginning in 2019, all of its cars will be The increase in the electric or hybrid number of IPOs models. worldwide in H1 2017. VOLVO There were 772 in total, The electric car market should soar doesn’t anticipate that the electric car including the US firm over the next two decades, with a fleet fleet will expand to that extent, but Snap (which raised consisting of 530 million vehicles by it certainly revised up its projections. $3.9 billion), the Korean 2040 according to a study conducted Despite the fact that OPEC’s 2015 pro- company Netmarble by Bloomberg New Energy Finance. The jections included a 46-million-vehicle ($2.3 billion) and the American agency concluded that as a fleet of electric cars by 2040, they have Chinese firm Guotai result, oil demand will drop by 8 million re-estimated that figure at five-fold its Junan ($2.2 billion). barrels by 2040, or the equivalent starting point, or 266 million vehicles. of current Iranian and Iraqi production The intergovernmental organisation combined. The Organization of the claims that electric cars will repre- Petroleum Exporting Countries (OPEC) sent 12% of the market in 2040. 6 SCANS SWISSQUOTE SEPTEMBER 2017 RANKING THE FIVE BRANDS THAT ARE WORTH THE MOST (calculated using consumer polls and company financial results) GRZEGORZ MICHALOWSKI / KEYSTONE 1. GOOGLE $246 BILLION 2. APPLE $235 BILLION 3. MICROSOFT $143 BILLION 4. AMAZON $139 BILLION 5. FACEBOOK $130 BILLION A 3D-printed implant. This technology is adaptable to the needs of each Source : annual BrandZ ranking compiled by WPP individual patient. THE FIVE QUIRKIEST BENEFITS SILICON VALLEY COMPANIES OFFER wellbeing THEIR EMPLOYEES GIVAUDAN : AN AROMATIC WAKE-UP CALL App developer Y Media has 1 rented a house in Hawaii that is available for its employees to use whenever they like Software developer Atlassian 2 gives its employees an unlimited “ From a number of paid holidays market The start-up Indeed provides its dynamics 3 employees with an insurance plan that enables them to be ROBYN BECK / AFP standpoint, repatriated by helicopter from anywhere in the world I’m absolutely The Geneva-based perfume expert convinced the Givaudan has decided to invest in Google, LinkedIn, Intel, Spotify, Sensorwake, a French start-up. The 4 Facebook, Microsoft and Amazon worst is over ” two joined forces to develop an alarm promise to pay the costs of IVF clock that wakes users not only via treatment for all employees. Antoine de Saint-Affrique, audio stimuli, but by diffusing morning Some of these companies also CEO of the B2B chocolate aromas “ that make you want to get finance the freezing of eggs manufacturer Barry Callebaut, during an out of bed ”, such as freshly-brewed coffee, cut grass, warm croissants Employees at GitHub are able interview with the Financial 5 to take advantage of free mas- Times.
Load more

Recommended publications
  • 5 EVENTS in ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland
    FIFTH ANNUAL - LIFE SCIENCE R&D DATA INTELLIGENCE LEADERS FORUM Basel, Switzerland January 23-24th, 2018 Optional Workshop 22nd, January Hear keynote presentations from the experts: Etzard Stolte Global Head Knowledge Management Roche, Switzerland Abhimanyu Verma 5 EVENTS IN ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland Day 1: Torsten Niederdraenk Head of Technology Center Strategic Developments in R&D Big Siemens Healthcare, Germany Data Catherine Brownstein Scientific Director Day 2 (am): Stream 1 Manton Center for Orphan Disease Research Boston Children’s Hospital, USA Discovery & Omics Data Excellence Navin Ramachandran Radiology Consultant Day 2 (am): Stream 2 University College London Hospitals NHS Foundation Trust, Healthcare specialist in distributed ledgers and IoT Clinical & Patient Level Data IOTA Foundation, UK Excellence Marie-Claire Peakman Executive Director, Head Hit Discovery & Lead Profiling, Medicine Design Day 2 (pm): Stream A Pfizer, USA R&D IT & Bioinformatics Alex Zhavoronkov Co-founder, Insilico Medicine, CSO Day 2 (pm): Stream B The Biogerontology Research Foundation, UK Ivana Schnur Digital Health Collaborations Co-founder, CMO Sense.ly, USA Pre-Event Workshop: Jan 22nd Paul Wicks Artificial Intelligence for Drug Vice President of Innovation PatientsLikeMe, UK Discovery: Workshop for Senior Jazz Panchoo Global Strategy Head, VP, Digital Platforms Executives Ascensia Diabetes Care, Switzerland This Event is Certified for Continuing Professional Development with more than 30 presentations
    [Show full text]
  • Swiss Biotech Report – "Agility, Leadership and Innovation in the Time of COVID-19” – Is Indeed Appropriate
    SwissSwiss BiotechBiotech ReportReport 2021 2019Agility, leadership and innovation in the time of COVID-19 Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra Swiss Confederation Innosuisse – Swiss Innovation Agency “The biopharma industry’s response to COVID-19 has truly been a global one – with Swiss companies and academic institutions at the forefront. Swiss-based biopharma players are contributing across the spectrum of patient needs.” George Scangos | Vir Biotechnology, Inc. “2020 was the best year ever for Swiss biotech in relation to financing activities, with a total of approximately CHF 3.4B raised” Jürg Zürcher | GSA Biotechnology Leader, EY “Compared to 2019, trading volumes rose sharply by 177% and the total free float market capitalization of all SIX-listed biotech companies was up 30% on 2020.” Fabian Gerber | SIX Agility, leadership and innovation in the time of COVID-19 “Technologies developed by scientists in Switzerland have been crucial in the fight against COVID-19, including cloning the virus, cryo electron microscopy to visualize the spike proteins, and the use of radioactive molecules that bind to receptor proteins to investigate how the virus enters the host.” Florian Fisch | Swiss National Science Foundation “On May 1 2020, Moderna and Lonza announced a strategic collaboration to enable manufacturing of up to 1 billion doses of the vaccine per year. Lonza acquired equipment and built the production lines in just 8 months.” Jan Lucht | scienceindustries “Industrial
    [Show full text]
  • European Human Genetics Conference 2017 Programme
    There’s nothing more 1967 - 2017 | 50th Anniversary Meeting personal than genomics Discover genomic solutions across the research continuum Visit us at stand 140 and discover how our portfolio of next-generation sequencing (NGS), microarray and informatic solutions can help empower your next breakthrough. EUROPEAN HUMAN Come learn how you can become a part of the scientic innovation happening in: GENETICS CONFERENCE 2017 • Complex Diseases • Rare or Undiagnosed Genetic Diseases Bella Center | Copenhagen, Denmark | May 27 - 30 • Reproductive Health • Cancer Genetics • Microbiology Experience the NovaSeq™ Series Discover a leap forward in technology by attending one of our stand presentations, or take a virtual reality tour. Attend the Illumina Satellite Workshop Sunday, 28 May | 19.15 – 20.45 | Room Ballerup Anniversary Meeting | Programme | European Human Genetics Conference 2017 | Copenhagen - Denmark 2017 | Copenhagen Human Genetics Conference | European Anniversary Meeting | Programme th 1967 - 2017 | 50 www.illumina.com Programme For Research Use Only. Not for use in diagnostic procedures. © 2017 Illumina, Inc. All rights reserved. European Society www.eshg.org @eshgsociety of Human Genetics facebook.com/eshg.org #eshg2017 GENERAL FLOORPLAN METRO Ground Floor Ballerup LECTURE HALLS B - CORPORATE SATELLITES Berlin Barcelona Brussels Birmingham Belgrade WC WC WC WC Bags Registration CENTERHALL Exhibition Service WC Athens Lead Retrieval Poster Printing LECTURE HALLS A Cambridge Gastro Café Exhibition Aarhus Centre Coffee & Lunch Preview Copenhagen Cash Bar MAIN LOBBY Live Stream Posters Amsterdam E-Posters WC AC Hotel FOYER Bella Sky LECTURE HALLS C Cannes Main Entrance Cologne First Floor 5 Athens CENTERHALL 16 17 WC 18 25 A Aarhus 18 19 20 LECTURE HALLS A Amsterdam MAIN LOBBY FOYER Ancona conf.
    [Show full text]
  • BOOKLET Santiago
    !1 14th International Symposium on Variants in the Genome: detection, sequencing & interpretation 5 - 7 June 2017 NH Collection Santiago Santiago de Compostela, Spain Scientific Programme Committee Prof. Johan T. den Dunnen (Leiden, Nederland) CHAIR Prof. Sir John Burn (Newcastle, UK) Prof. Angel Carracedo (Santiago de Compostela, Spain) Dr Reece Hart (San Francisco, CA, USA) Dr Andreas Laner (Munich, Germany) Dr Maria-Jesus Sobrido (Santiago de Compostela, Spain) Organising Committee Maria Torres (CEGEN-PRB2, Universidade de Santiago de Compostela) Rania Horaitis; Event Manager (Meeting Makers www.meeting-makers.com) Previous Meetings 2003 Palm Cove, Australia 1991 Oxford, UK 2005 Santorini, Greece 1993 Lago D’Orta, Italy 2007 Xiamen, China 1995 Visby, Sweden 2009 Paphos, Cyprus 1997 Brno, Czech Republic 2011 Santorini, Greece 1999 Vicoforte, Italy 2013 Lake Louise, Canada 2001 Bled, Slovenia 2015 Leiden, Netherlands !2 !3 !4 !5 !6 !7 !8 !9 !10 !11 !12 !13 Oral Presentation Abstracts Exomiser to include an assessment of SESSION 1 regulatory regions, in an application called the Genomiser. Simulations show an ability to rank the seeded causative variant in first place Phenotype Driven Genomic over an entire genome in over 60% of cases. Diagnostics In this talk, I will review how computational phenotype analysis with the HPO works and Peter N Robinson how we have used it for the Exomiser and Genomiser. Professor of Computational Biology, The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT 06032, USA CNV detection from targeted [email protected] next-generation panel sequencing www.jax.org Robinson lab: https://robinsongroup.github.io/ data in routine diagnostics Anna Benet-Pagès, Anke M.
    [Show full text]
  • Sophia GENETICS SA (Exact Name of Registrant As Specified in Its Charter)
    As filed with the Securities and Exchange Commission on July 23, 2021 Registration No. 333-__________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Rue du Centre 172, CH-1025 Saint-Sulpice, Switzerland (Address of Principal Executive Offices) SOPHiA GENETICS Incentive Stock Option Plan SOPHiA GENETICS 2019 Incentive Stock Option Plan (Full title of the plans) SOPHiA GENETICS, Inc. 185 Dartmouth Street, Suite 502 Boston, MA 02116 (Name and Address of Agent For Service) (617) 982-1210 (Telephone number, Including Area Code, of Agent For Service) Copies of all communications, including all communications sent to the agent for service, should be sent to: Kyoko Takahashi Lin Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 (212) 450-4000 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller reporting company o (Do not check if a smaller reporting company) Emerging Growth Company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
    [Show full text]
  • ESMO 2019 Exhibitors' List
    ESMO 2019 - Exhibitors' list (as of 21 of August 2019) Booth Number Company name 441 3D TECH OMEGA ZETA 469 3DforScience - Visuals for Bio & Health 235 10x Genomics 315 AbbVie 227 Abcam 213 Accord Healthcare 471 Adaptive Biotechnologies 208 Advanced Accelerator Applications, a Novartis company 465 Agendia 456 Alkermes, Inc 473 Almac Group 403 Amgen Inc. 415 Amoy Diagnostics Co., Ltd. 211 Aptitude Health 248 ArcherDX 309 Astellas 305 AstraZeneca 467 Avaden BioSciences, Inc. 463 Axiom Healthcare Strategies 446 Baxter 306 Bayer 419 BEACON Medicare Limited 443 BEIGENE, LTD. 233 Biocartis 245 Biotype GmbH 302 Bristol-Myers Squibb 401 Boehringer Ingelheim 238 Calithera Biosciences 476 Cancer Drug Interactions 407 Caris Life Sciences 225 CATALYSIS S.L. 318 CeGaT 215 Celgene 409 Celltrion Healthcare Co., Ltd. 454 Chemo Mouthpiece 450 Clinical Research Malaysia 217 Clovis Oncology 421 COMECER 411 Covance, Inc. 462 Cytel 205 Daiichi Sankyo, Inc. 413 DAVA Oncology 452 ECS Progastrin 207 Eisai Ltd. 229 Elevar 239 EntroGen 247 Erytech Pharma SA 440 Europital 402 EUSA Pharma 214 Exelixis, Inc. 303 F. Hoffmann-La Roche AG 458 Ferring Pharmaceuticals 244 FibroGen, Inc. 455 FRENCH HEALTHCARE 422 Fresenius Kabi 448 geneXplain GmbH 221 Genmab 404 GENOMIC HEALTH 206 GSK 249 Guardant Health 246 HalioDx 474 Halozyme Therapeutics 417 Helsinn Healthcare 445 HTG Molecular Diagnostics 251 IBM Watson Health 319 Illumina 477 ImaginAb, Inc. 216 Incyte Biosciences International Sàrl 242 Institut Curie 310 IPSEN 472 IQVIA Biotech 210 ITM Isotopen Technologien Muenchen AG 220 Janssen-Cilag International NV P432 Jiahui International Hospital 406 Kaiku Health 420 Kite, a Gilead Company 236 KoNECT (Korea National Enterprise for Clinical Trials) 475 Leica Biosystems 307 Lilly 237 Linical 204 Loxo Oncology, Inc.
    [Show full text]
  • Cynosure Aces Single-Audit Program Twice
    POLICY & REGULATION COMMERCIAL R&D An update on NEST real-world Mark Hitchman of Canon Medical Two firms nab US breakthrough evidence efforts, p. 6 Systems discusses market growth status, p. 22 strategies, p. 15 Medtech Issue 80 Pharma Intelligence Informa February 5, 2018 medtech.pharmaintelligence.informa.comInsight 'WE SURVIVED MDSAP': The final visit from the US agency that year was the last straw, she said. "That FDA inspection really made me Cynosure Aces Single-Audit Program want to get Cynosure involved in MDSAP because I cancelled a vacation to Indonesia Twice; Tells How Your Firm Can, Too to stay behind for that inspection," Hoy said. "That's when I learned that travel insurance SHAWN M. SCHMITT [email protected] doesn't consider an FDA inspection to be an emergency that's reimbursable." MDSAP , created by the International Medical Device Regulators Forum (IMDRF), allows firms to undergo only one audit by an accredited third party to satisfy quality regulations for five countries: the US, Can- ada, Brazil, Japan and Australia. The program runs on a three-year cycle, albeit with differing scopes for each audit. Firms are certified to MDSAP in the first year; in the second and third years, they submit to surveillance audits, which are typically quicker than a certification audit. The cycle then repeats, with recertification to MDSAP Shutterstock: alphaspirit Shutterstock: occurring in the fourth year, and so on. MDSAP ran as a pilot program for three or longtime quality and regulatory "It was particularly difficult that year to full years from January 2014 through expert Connie Hoy, the decision to be in the quality department at Cynosure December 2016, but is now a bona-fide F ditch the prying eyes of multiple because all we did was get audited.
    [Show full text]
  • People Recent Moves of Note in and Around the Biotech and Pharma Industries
    careers & recruitment People Recent moves of note in and around the biotech and pharma industries. held various leadership roles at Novartis, Turning Point Therapeutics has announced the appointment including development franchise head of of Siegfried Reich (photo) as executive vice president respiratory, development franchise head of and CSO. Reich has over 25 years of pharma and biotech primary care, and global head of clinical experience developing more than 20 drug candidates. He was operations, analytics and regions. most recently senior vice president of research and cofounder of eFFECTOR Therapeutics, and before that was vice Michael Quigley has joined Gilead Sciences president and head of drug discovery at SGX, vice president as senior vice president, research biology. and head of viral and ophthalmic diseases at Pfizer, and He was most recently vice president and director and head of medicinal chemistry at Agouron. head of Bristol-Myers Squibb’s thematic “With a strong commitment to build on the four internally discovered drug research center for tumor microenvironment candidates in our pipeline, we wanted to attract a proven leader and visionary CSO modulation and site head of its Redwood to advance our research strategy,” said Athena Countouriotis, president and CEO of City, California location. Turning Point. “Siegfried is an ideal fit for our team, with deep discovery and novel- target-identification expertise, and a proven track record of developing drug candidates Verana Health has appointed Matthew Roe for difficult-to-drug targets through disciplined discovery and medicinal, structure- and chief medical officer. Roe is a cardiologist fragment-based chemistry.” and clinical researcher who has spent over two decades at the Duke University School of Medicine and the Duke Clinical Research Robert Abraham has been named CSO Therapeutics.
    [Show full text]
  • Sophia GENETICS SA Ordinary Shares This Is an Initial Public Offering of Ordinary Shares by Sophia GENETICS SA
    Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257646 Prospectus 13,000,000 Shares SOPHiA GENETICS SA Ordinary Shares This is an initial public offering of ordinary shares by SOPHiA GENETICS SA. We are offering 13,000,000 ordinary shares. The initial public offering price is $18.00 per ordinary share. Prior to this offering, there has been no public market for our ordinary shares. Our ordinary shares have been approved for listing on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “SOPH.” Instrumentarium Holdings, Inc., an affiliate of GE Precision Healthcare LLC (“GE Healthcare”), has agreed to purchase $20.0 million of our ordinary shares in a private placement concurrent with and contingent upon the completion of this offering, with the price per share to be equal to the initial public offering price in this offering. The sale of such ordinary shares will not be registered under the Securities Act of 1933, as amended (the “Securities Act”). The closing of this offering is not contingent upon the closing of such concurrent private placement. We will not pay any underwriting discounts or commissions for the ordinary shares sold in the concurrent private placement. See “Prospectus Summary—Recent Developments—Private Placement.” We are an “emerging growth company” as defined under U.S. federal securities laws and, as such, may elect to comply with reduced public company reporting requirements for this and future filings. See “Prospectus Summary—Implications of Being an Emerging Growth Company.” Per Share Total Initial public offering price $ 18.00 $234,000,000 Underwriting discounts and commissions(1) $ 1.26 $ 16,380,000 Proceeds to SOPHiA GENETICS SA, before expenses $ 16.74 $217,620,000 (1) See “Underwriting” for a description of all compensation payable to the underwriters.
    [Show full text]
  • Swiss Biotech Report 2020
    Swiss Biotech Report 2020 Jürg Zürcher and Michael Altorfer April 21, 2020 Swiss biotech hub: A tight cross-functional network Veterinary R&D CMO Bio-IT Analytical Therapeutics Engineering Swiss Biotech Cell culture Hub Food & industrial Medtech Biotech consulting Diagnostics Agriculture Chemicals reagents Labware Bio-equipment Non-biotech consulting April 21, 2020 3 Swiss Biotech Report 2020: Continued sector growth • Biotech industry generates revenues of CHF 4.8 billion in 2019, up from CHF 4.0 billion in 2018 • Over CHF 1 billion raised for private and public companies • Licensing deals and collaborations boost revenues • Gene therapy, AI and advanced biologics manufacturing emerging as additional strengths • Over 40 new start ups set up in 2019 April 21, 2020 4 Life sciences account for 40% of Swiss exports Pharma and biotech together CHF 97.5 bn in 2019 April 21, 2020 5 Emerging new strengths Manufacturing of complex biologicals and exploitation of AI • Biogen, CSL Behring, Novartis and Merck invest heavily in expanding production capacity • Increasing number of complex biologicals and cell therapies gain approval • AI being exploited by companies such as SOPHiA GENETICS, BC Platforms, Genedata, Insphero, GenomSys and SimplicityBIO April 21, 2020 6 Artificial intelligence: Emerging business opportunities Interviews with Jurgi Camblong, SOPHiA GENETICS and Axel Nemetz, IBM • AI applications offer new business opportunities in healthcare • SOPHiA GENETICS and IBM represent two complementary examples • Both develop globally applicable
    [Show full text]
  • Switzerland's Biotech
    Switzerland’s biotech hub - a powerful source of innovation AFSSI Connexions, Convention 2019, July 2nd, Lyon Michael Altorfer CEO, Swiss Biotech Association The Swiss biotech industry is a key asset Switzerland is one of the best Local companies hold and most innovative locations leading positions throughout many for biotechnology in Europe and sectors and thus attract capital and the world researchers from all over the world The basis for this success is a In addition to being an attractive close-knit network between place to live for international research and development, driven specialists, Switzerland also offers a by renowned universities, highly modern infrastructure, a specialized SMEs and strong beneficial funding environment multinational corporations and access to a highly-qualified workforce 2 swissbiotech.org A tight cross-functional network Veterinary R&D CMO Bio-IT Analytical Therapeutics Engineering SBA member company activities Cell culture Food & industrial Medtech Biotech consulting Diagnostics Agriculture Chemicals reagents Labware Bio-equipment Non-biotech consulting 3 swissbiotech.org Swiss Biotech: Structural changes offer new investment and partnering opportunities CRO share research risk Biotech companies stay independent: CMOs take over production sites • build their commercial Clinical trials are outsourced organizations and even financed by partners • partner with distributors team up with partners Service providers start that have access to SBA member sharing risks and benefit patients company activities • combine drug and Business models not relying medical device or on product development service provider Investors go it alone, build Some Biotech companies are virtual project teams rather fully financed, eliminating the than companies need for small incremental financing rounds 4 swissbiotech.org Capital investment in Swiss biotech companies 5 Swiss Biotech Day 2019 From 2007 - 2018 Venture Kick invested CHF 3.16 million in 48 Swiss biotech startups.
    [Show full text]
  • 25 to 26 September 2019 Heidelberg | Germany European Business
    Programme © Matthias Bach European Business Development Conference 25 to 26 September 2019 Heidelberg | Germany Local Hosts: Gold Sponsorships: Silver Sponsorship: Conference Supporters: Wednesday, 25 September Thursday, 26 September MORNING PROGRAMME: STARTING 10.00 AM Partnering / Breakfast: Starting 08.00 AM Opening Remarks Rainer Wessel, Director Innovation Management, DKFZ MORNING PROGRAMME: STARTING 09.00 AM Keynote Oncology Keynote Digitization / AI in Health Care Joern-Peter Halle, SVP, Head of TIP Immuno Oncology and Lorenz Mayr, Chief Technology Officer, GE Healthcare Head of External Innovation, Merck Company Presentations Company Presentations Chair: Ruth Herzog, Head of Technology Transfer, DKFZ Chair: Uwe Hanenberg, Director Product Development and • Molecular Health Director S&T, Catalent Pharma Solutions • CEVEC Pharmaceuticals • YUMAB • ALBEGA Medical • PEPperPRINT • MI-mAbs • Proteona • Immunic Session 3 • Phenex Pharmaceuticals Drug Development 4.0 – How Digitization and AI Change Drug Development Chair: Károly Földesi, Director Digital Business for Life Partnering / Lunch Sciences Germany, SAP Deutschland SE & Co. KG Confirmed Speakers: AFTERNOON PROGRAMME: STARTING 14.15 PM • Esteban Czwan, SVP Clinical Trials Business Area, Sophia Genetics Session 1 • David Harel, Chief Executive Officer, CytoReason Fighting Malignancies – Focus on Cancer Therapy • Edith Schallmeiner, Commercial Director, Customer Chair: Ulrich Zügel, Director External Science & Innovation Success EMEA-LATAM, Diagnostics Information Germany, Pfizer
    [Show full text]